Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Glioma × mirdametinib × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neurofibromatosis 1 3 Neurofibromatoses 2 Neurofibroma 2 Melanoma 2 Colorectal Neoplasms 2 Breast Neoplasms 2 Vascular Malformations 1 Solid Tumor, Adult 1 Skin Diseases, Vascular 1 Primary Malignant Peripheral Nerve Sheath Tumors 1 Oligodendroglioma 1 Neurofibroma, Plexiform 1 Neurocytoma 1 Neoplasms, Neuroepithelial 1 NF1 1 Multiple Myeloma 1 Lymphatic Abnormalities 1 Lymphangioma, Cystic 1 Lymphangioma 1 Liposarcoma, Myxoid 1 Liposarcoma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 KRAS Mutant Non-Small Cell Lung Cancer 1 Glioma 1 Glioblastoma 1 Ganglioneuroma 1 Ganglioglioma 1 Colonic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Astrocytoma 1

Interventions

Temozolomide 155 Bevacizumab 68 Radiotherapy 61 Magnetic Resonance Spectroscopy 58 Irinotecan 31 Surgical Procedures, Operative 23 Radiation 23 Carboplatin 23 Specimen Handling 20 Carmustine 20 Nivolumab 19 Biopsy 17 Lomustine 15 Aminolevulinic Acid 15 Radiotherapy, Intensity-Modulated 13 trametinib 12 pembrolizumab 12 Radiosurgery 12 Erlotinib Hydrochloride 12 Cyclophosphamide 12 Topotecan 11 Everolimus 11 fluorodopa F 18 10 X-Rays 10 IL13-PE38 10 Blood Specimen Collection 10 dabrafenib 9 Etoposide 9 ribociclib 8 poly ICLC 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07521657 2026-04-13

NF118

University of Alabama at Birmingham

Phase 2 Not yet recruiting

Glioblastoma, Glioma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡